Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inhaled adrenergic bronchodilators: historical development and clinical application.

J L Rau1

  • 1Cardiopulmonary Care Sciences, Georgia State University, Atlanta 30303-3083, USA. jrau@gsu.edu

Respiratory Care
|August 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introduction of a single isomer beta agonist.

Respiratory care·2000
Same author

New horizons in respiratory care: the pharmacology of inhaled aerosol drug therapy.

Respiratory care·2000
Same author

Combining a positive expiratory pressure device with a metered-dose inhaler reservoir system using chlorofluorocarbon albuterol and hydrofluoroalkane albuterol: effect on dose and particle size distributions.

Respiratory care·2000
Same author

The evolution of beta-agonists.

Respiratory care clinics of North America·1999
Same author

Recent developments in respiratory care pharmacology.

Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses·1999
Same author

Reservoir design and dose availability with long-term metered dose inhaler corticosteroid use.

Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine·1999

Newer inhaled adrenergic bronchodilators offer improved receptor specificity and longer duration of action for asthma patients. Levalbuterol provides a single isomer option, enhancing treatment choices for reversible obstructive lung disease.

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • Adrenergic bronchodilators have evolved with enhanced receptor specificity and duration.
  • Inhaled aerosols target the lungs directly for efficient drug delivery.
  • Beta-agonist bronchodilators provide convenient dosing, with durations from 4-6 hours to 12 hours (salmeterol).

Observation:

  • Levalbuterol, a single isomer active on beta-2 receptors, is now available.
  • Current bronchodilators offer sophisticated options for airway smooth muscle relaxation.
  • Despite safety and reduced adverse effects, concerns remain regarding beta-agonist use in asthma.

Findings:

  • The development of adrenergic bronchodilators has led to improved receptor specificity and duration of action.
  • Levalbuterol represents a refinement, offering a single active isomer for beta-2 receptor targeting.

Related Experiment Videos

  • Clinicians and patients have a wider selection of advanced drugs for reversible obstructive lung diseases.

    • Implications:

    • Improved bronchodilator options enhance airway smooth muscle relaxation for obstructive lung diseases.
    • Further understanding of asthma pathophysiology may optimize the use of beta agonists.
    • Ongoing research aims to address persistent concerns about beta-agonist efficacy and safety in asthma management.